Cookie Settings

We use cookies to optimize our website. These include cookies that are necessary for the operation of the site, as well as those that are only used for anonymous statistic. You can decide for yourself which categories you want to allow. Further information can be found in our data privacy protection .

Essential

These cookies are necessary to run the core functionalities of this website and cannot be disabled.

Name Webedition CMS
Purpose This cookie is required by the CMS (Content Management System) Webedition for the system to function correctly. Typically, this cookie is deleted when the browser is closed.
Name econda
Purpose Session cookie emos_jcsid for the web analysis software econda. This runs in the “anonymized measurement” mode. There is no personal reference. As soon as the user leaves the site, tracking is ended and all data in the browser are automatically deleted.
Statistics

These cookies help us understand how visitors interact with our website by collecting and analyzing information anonymously. Depending on the tool, one or more cookies are set by the provider.

Name econda
Purpose Statistics
External media

Content from external video platforms is blocked by default. If cookies from external media are accepted, access to this content no longer requires manual consent.

Name Youtube
Purpose External media

DKFZ Junior Group Brain Tumor Translational Targets

Dr. Violaine Goidts

Targeting GSCs to achieve complete degeneration of glioblastoma; a) Currently, the resistance of GSCs to radio- and chemotherapy allows this rare subpopulation of cells to persist after GBM treatment. Patients relapse with an aggressive tumour enriched in GSCs. b) Targeting GSCs with additional therapeutics will deplete this resistant sub-population, allowing complete degeneration of the tumour.
© dkfz.de

Due to its location, aggressiveness and diffuse growth pattern, glioblastoma therapy is tremendously challenging and advances in the field are urgently needed. Much evidence has been gathered to reveal a small sub-population of cancer cells, known as glioblastoma stem-like cells (GSCs), which are thought to be responsible for the current therapy resistance of glioblastoma. In this respect, considerable effort must be directed towards the targeting of GSCs.
Recently, the advent of high-throughput next-generation sequencing technologies has led to a new era in the study of de novo mutations, helping to uncover disease precondition and mechanism. However, these informative analyses do not account for post-translational modifications. High-throughput phenotypic screens, which form the basis of the strategy of our group, have proven to resolve this issue and offer a large panel of candidate genes or small-molecule inhibitors.
This great resource provided by these functional screens supports our ambition to further discover new druggable therapeutic targets or new compounds to treat glioblastoma. We aim to verify their efficacy in pre-clinical studies and to test them in clinical trials.

Contact

Dr. Violaine Goidts
Brain Tumor Translational Targets (B067)
Deutsches Krebsforschungszentrum
Im Neuenheimer Feld 580
69120 Heidelberg
Tel: +49 6221 42-4635

Selected Publications

  • Kim S.H. et al. (2016). Serine/Threonine kinase MLK4 determines Mesenchymal Identity in Glioma Stem Cells in an NF-?B-dependent manner. Cancer Cell, 29, 201-213.
  • Phillips E. et al. (2016). Targeting atypical protein kinase C iota reduces viability in glioblastoma stem-like cells via a notch signaling mechanism. Int J Cancer, 139, 1776-1787.
to top
powered by webEdition CMS